Get the Stockscreener App
20.22
0.69%
-0.14
Anaptysbio Inc stock is traded at $20.22, with a volume of 257.92K.
It is down -0.69% in the last 24 hours and down -22.85% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$20.36
Open:
$20.43
24h Volume:
257.92K
Relative Volume:
0.47
Market Cap:
$566.10M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-3.3257
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+0.40%
1M Performance:
-22.85%
6M Performance:
+8.77%
1Y Performance:
-45.78%
1-Day Range:
$20.09
$21.04
1-Week Range:
$19.48
$21.04
52-Week Range:
$12.21
$40.70
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
20.22 | 560.02M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Trend analysis for AnaptysBio Inc. this weekSwing Trade & Expert Curated Trade Setups - Newser
Fox Run Management L.L.C. Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Will AnaptysBio Inc. continue its uptrend2025 Buyback Activity & Consistent Profit Focused Trading Strategies - Newser
Can a trend reversal in AnaptysBio Inc. lead to recoveryJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Earnings visualization tools for AnaptysBio Inc.Market Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
Historical volatility pattern of AnaptysBio Inc. visualizedJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
How to manage a losing position in AnaptysBio Inc.2025 Top Decliners & Community Consensus Trade Signals - Newser
How to read the order book for AnaptysBio Inc.Weekly Risk Report & Weekly Stock Performance Updates - Newser
Chart based exit strategy for AnaptysBio Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
Will AnaptysBio Inc. stock go up soonBreakout Watch & Risk Controlled Swing Trade Alerts - Newser
Will breakout in AnaptysBio Inc. lead to full recoveryJuly 2025 Closing Moves & Free Community Supported Trade Ideas - Newser
What does recent volatility data suggest for AnaptysBio Inc.Quarterly Portfolio Report & Real-Time Volume Analysis - Newser
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Investigational Rosnilimab Emerges as a Novel, Differentiated Treatment Option for Rheumatoid Arthritis - Fierce Biotech
Can machine learning forecast AnaptysBio Inc. recoveryJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
What makes AnaptysBio Inc. stock price move sharplyEarnings Trend Report & Weekly Breakout Opportunity Watchlist - mustnews.co.kr
UBS Group Reiterates Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Multi asset correlation models including AnaptysBio Inc.Layoff News & Long-Term Growth Stock Strategies - Newser
Is AnaptysBio Inc. a good stock for dollar cost averaging2025 Price Action Summary & Smart Allocation Stock Tips - sundaytimes.kr
Will AnaptysBio Inc. see short term momentumTrade Risk Summary & Consistent Return Strategy Ideas - Newser
How to recover losses in AnaptysBio Inc. stockPortfolio Return Report & Verified High Yield Trade Plans - Newser
Federated Hermes Inc. Lowers Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Inc. stock trend forecastTrade Volume Summary & Entry Point Strategy Guides - Newser
Wedbush Forecasts AnaptysBio's Q3 Earnings (NASDAQ:ANAB) - MarketBeat
Leerink Partnrs Forecasts Stronger Earnings for AnaptysBio - MarketBeat
Is AnaptysBio Inc. a defensive stock2025 Geopolitical Influence & Daily Profit Maximizing Trade Tips - kangso.co.kr
What technical models suggest about AnaptysBio Inc.’s comebackJuly 2025 Institutional & Momentum Based Trading Ideas - Newser
AnaptysBio’s (ANAB) Neutral Rating Reaffirmed at UBS Group - Defense World
AnaptysBio (NASDAQ:ANAB) Earns Neutral Rating from UBS Group - Defense World
AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group - Defense World
AnaptysBio Inc. Matches Institutional Buying FilterMarket Trend Report & Weekly High Conviction Ideas - 선데이타임즈
UBS Maintains AnaptysBio(ANAB.US) With Hold Rating, Cuts Target Price to $20 - 富途牛牛
UBS Adjusts Price Target on AnaptysBio to $20 From $18, Maintains Neutral Rating - MarketScreener
What is Wedbush's Estimate for AnaptysBio Q4 Earnings? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 9.8%Should You Sell? - MarketBeat
UBS Raises AnaptysBio PT to $20, Maintains Neutral Rating - AInvest
Wedbush Raises AnaptysBio (NASDAQ:ANAB) Price Target to $45.00 - MarketBeat
AnaptysBio Receives Hold Rating from Truist Financial with $20 Target - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wedbush Weighs in on AnaptysBio’s Q3 Earnings (NASDAQ:ANAB) - Defense World
Federated Hermes Inc. Has $154,000 Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
What moving averages say about AnaptysBio Inc.Downside Control Plan With Support Analysis - Newser
AnaptysBio Reports Q2 2025 Financial Results and Updates - TipRanks
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $45.00 - Defense World
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RENTON HOLLINGS | Director |
Aug 08 '25 |
Sale |
19.62 |
10,231 |
200,714 |
4,965 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):